SCHEDULE: HOLD Alapkezelo Zrt. Discloses 5.2% Stake in Protalix BioTherapeutics

HOLD Alapkezelo Zrt. has reported beneficial ownership of 4,157,791 shares, representing 5.2% of Protalix BioTherapeutics, Inc.'s common stock.

Summary

• HOLD Alapkezelo Zrt. has filed a Schedule 13G, indicating it beneficially owns 4,157,791 shares of Protalix BioTherapeutics, Inc. common stock.
• This ownership stake represents approximately 5.2% of the company's outstanding common shares as of June 30, 2026.
• The filing is made under Rule 13d-1(b), classifying HOLD Alapkezelo Zrt. as a Hungarian investment fund management company.
• The reporting person has sole voting power and sole dispositive power over these shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new strategic or financial information.

Positives

• HOLD Alapkezelo Zrt. has acquired a significant stake, potentially indicating confidence in Protalix BioTherapeutics' future prospects.
• The clear disclosure of sole voting and dispositive power suggests straightforward control over the reported shares.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Protalix BioTherapeutics.
• The information is limited to ownership disclosure, offering no insight into the company's operational health.

Risks

• The filing does not explicitly mention any risks associated with the ownership stake or Protalix BioTherapeutics' operations.
• Potential future changes in HOLD Alapkezelo Zrt.'s ownership could impact Protalix BioTherapeutics' stock stability.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Protalix BioTherapeutics, Inc. or HOLD Alapkezelo Zrt.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds. This filing indicates a significant institutional investor's presence in the biotechnology sector, specifically within Protalix BioTherapeutics' shareholder base.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by an institutional investor may influence market perception and potentially stock price volatility.
• Management: The increased institutional ownership may lead to closer scrutiny of company performance and governance by HOLD Alapkezelo Zrt.

Next Steps

• HOLD Alapkezelo Zrt. will continue to hold its shares in Protalix BioTherapeutics, Inc.
• Protalix BioTherapeutics, Inc. will continue its operations and business activities as usual, subject to shareholder oversight.

Key Dates

Keywords

Protalix BioTherapeutics, Schedule 13G, Beneficial Ownership, HOLD Alapkezelo Zrt., Investment Fund, Common Stock, Hungary